A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Ruxolitinib (Primary) ; Pembrolizumab
- Indications Breast cancer
- Focus Adverse reactions
- 08 Dec 2017 Planned End Date changed from 1 Mar 2020 to 15 Mar 2020.
- 08 Dec 2017 Planned primary completion date changed from 1 Mar 2020 to 15 Mar 2020.
- 08 Dec 2017 Status changed from not yet recruiting to recruiting.